Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, filed this Form 6-K on March 10, 2022. The filing serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose a press release and does not contain a financial statement or detailed financial data.
Material Changes
The filing text does not provide information regarding material changes versus prior periods. The content is limited to the notification of the press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details are contained within the attached press release (Exhibit 99.1), the text of which is not included in the provided input.
Key Facts for Investor Verification
- Verify the content of the press release dated March 10, 2022, referenced as Exhibit 99.1, as the filing itself contains no operational or financial details.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on March 10, 2022.